Expression of the Multidrug-Resistance 1 (MDR1) Gene and Prognosis in Human Pancreatic Cancer
- 1 October 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Pancreas
- Vol. 21 (3) , 240-247
- https://doi.org/10.1097/00006676-200010000-00004
Abstract
Multidrug-resistance 1 (MDR1) encodes a 170-kDa transmembrane glycoprotein (P-glycoprotein), which acts as a drug-efflux pump. In the present study, we analyzed the expression of MDR1/P-glycoprotein in human pancreatic cancer and correlated the results with clinical parameters. Pancreatic cancer tissue samples were obtained from 67 patients (30 female, 37 male) who underwent surgery. Normal pancreatic tissues obtained from 15 previously healthy organ donors (4 female, 11 male) served as controls. MDR1 mRNA levels were analyzed by Northern blotting, and the exact site of MDR1 mRNA expression was determined by in situ hybridization and immunohistochemistry. Northern blot analysis indicated that in comparison with the normal pancreas, MDR1 mRNA levels were only increased 1.4-fold (p = 0.03) in the pancreatic cancer samples. However, there was a 2.9-fold (p < 0.01) increase in MDR1 mRNA levels when only the samples that exhibited increased expression (38%) were analyzed. In situ hybridization and immunohistochemical analysis showed that MDR1 was highly expressed in the cancer cells of these samples. Statistical analysis revealed that patients with high MDR1/P-glycoprotein expression had a shorter postoperative survival time compared with patients with weak to moderate expression of MDR1. On the basis of in situ hybridization, survival in the intense group was 11.6 (n = 12) versus 14.2 months (n = 42) in the mild to moderate group. On the basis of immunohistochemistry, survival in the intense group was 7.5 months (n = 10) versus 14.1 months (n = 40) in the mild to moderate group. Surprisingly, survival of patients with high expression of MDR1/P-glycoprotein was not significantly different from that of patients without detectable MDR1/P-glycoprotein expression. These findings suggest that both strong expression of MDR1/P-glycoprotein and lack of expression seem to influence tumor growth via known and yet unknown mechanisms.Keywords
This publication has 22 references indexed in Scilit:
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- MDR1 gene expression in solid tumoursEuropean Journal Of Cancer, 1996
- Immunohistochemical Localization of P-Glycoprotein and Expression of the Multidrug Resistance-1 Gene in Human Pancreatic Cancer: Relevance to Indicator of Better PrognosisJapanese Journal of Cancer Research, 1996
- MDR1 gene expression: Evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomasEuropean Journal Of Cancer, 1996
- Restricted infection with canine distemper virus leads to down-regulation of myelin gene transcription in cultured oligodendrocytesActa Neuropathologica, 1995
- P-glycoproteins: mediators of multidrug resistanceSeminars in Cell Biology, 1993
- Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha.Journal of Clinical Investigation, 1992
- Treatment of Duct Carcinoma of the Pancreas with the LH-RH Analogue BuserelinPancreas, 1992
- A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancerCancer, 1991
- Detection of mRNAs in sea urchin embryos by in situ hybridization using asymmetric RNA probesDevelopmental Biology, 1984